Astrana Health (NASDAQ:ASTH) Cut to Strong Sell at Zacks Research

Zacks Research downgraded shares of Astrana Health (NASDAQ:ASTH) from a hold rating to a strong sell rating in a research note released on Tuesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on ASTH. Weiss Ratings reiterated a “sell (d+)” rating on shares of Astrana Health in a research report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrana Health in a research report on Tuesday, November 25th. Barclays dropped their price target on shares of Astrana Health from $36.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Monday, November 24th. TD Cowen reduced their price objective on shares of Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Finally, Needham & Company LLC began coverage on shares of Astrana Health in a research report on Friday, December 12th. They issued a “buy” rating and a $28.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Astrana Health presently has an average rating of “Moderate Buy” and a consensus price target of $40.78.

Astrana Health Trading Down 4.6%

Shares of Astrana Health stock opened at $18.16 on Tuesday. The firm has a 50-day simple moving average of $24.13 and a two-hundred day simple moving average of $26.65. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.40 and a current ratio of 1.40. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $39.97. The company has a market cap of $1.02 billion, a P/E ratio of 95.58, a price-to-earnings-growth ratio of 0.57 and a beta of 0.90.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ASTH. Signaturefd LLC grew its position in shares of Astrana Health by 57.9% in the fourth quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock valued at $26,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC grew its holdings in Astrana Health by 144.7% in the 4th quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock valued at $37,000 after buying an additional 871 shares in the last quarter. Strs Ohio acquired a new stake in shares of Astrana Health in the 4th quarter worth $40,000. Covestor Ltd grew its holdings in shares of Astrana Health by 210.6% in the third quarter. Covestor Ltd now owns 3,233 shares of the company’s stock valued at $92,000 after purchasing an additional 2,192 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after purchasing an additional 3,517 shares during the period. 52.77% of the stock is owned by hedge funds and other institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.